Thieme H, Renieri G, Schuart C
Universitätsaugenklinik, Leipziger Str. 44, 39120, Magdeburg, Deutschland,
Ophthalmologe. 2013 Dec;110(12):1149-54. doi: 10.1007/s00347-012-2676-y.
The pharmaceutical therapy of glaucoma dates back to 1875 when Weber introduced pilocarpine into the medicinal treatment of glaucoma. Since then there has been a continuous development of topical antiglaucoma therapy whereby the main developments date back to the 1980s and 1990s. All forms of medicinal therapy aim at lowering the intraocular pressure and achieve this either by inhibiting aqueous humor secretion into the ciliary body or by enhancing physiological drainage routes along Schlemm's canal. This article gives an overview over the most important classes of antiglaucoma drugs, the indications and contraindications as well as pharmacological characteristics. The focus lies on the market of combination and generic drug preparations that is currently rapidly developing and therefore needs to be discussed in detail.
青光眼的药物治疗可追溯到1875年,当时韦伯将毛果芸香碱引入青光眼的药物治疗。从那时起,局部抗青光眼治疗不断发展,主要发展阶段可追溯到20世纪80年代和90年代。所有药物治疗形式的目的都是降低眼压,这要么是通过抑制房水向睫状体的分泌,要么是通过增强沿施莱姆管的生理引流途径来实现。本文概述了最重要的抗青光眼药物类别、适应证和禁忌证以及药理学特性。重点在于目前正在迅速发展的复方和仿制药制剂市场,因此需要详细讨论。